Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Viridian Therapeutics, Inc.

R&D Spending Trends: Bausch Health vs. Viridian Therapeutics

__timestampBausch Health Companies Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 2014246000000293000
Thursday, January 1, 20155828000001002000
Friday, January 1, 2016455000000888000
Sunday, January 1, 201736600000019623000
Monday, January 1, 201841400000030421000
Tuesday, January 1, 201947100000034794000
Wednesday, January 1, 202045200000028304000
Friday, January 1, 202146500000056886000
Saturday, January 1, 2022529000000100894000
Sunday, January 1, 2023604000000159765000
Loading chart...

Cracking the code

A Decade of Innovation: R&D Spending Trends

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Bausch Health Companies Inc. and Viridian Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.

Bausch Health has consistently increased its R&D spending, peaking in 2023 with a 145% rise from 2014. This growth underscores their strategic focus on expanding their product pipeline. In contrast, Viridian Therapeutics, Inc. has shown a remarkable surge, with a staggering 54,000% increase in R&D expenses from 2014 to 2023, reflecting their aggressive push into new therapeutic areas.

These trends highlight the dynamic nature of the pharmaceutical industry, where strategic R&D investments can drive future growth and innovation. As these companies continue to evolve, their R&D strategies will be pivotal in shaping their competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025